List of Small Molecule Pharmaceuticals Companies in South Korea - 65

At 1STBIO, we strive to transform the lives of patients by relentlessly discovering and developing novel therapeutics to address areas of significant unmet need. Inspired by science and innovation, we dedicate our expertise and experience in drug development to bring forward a pioneering change.

AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.

Aston Sci., a clinical stage biopharmaceutical company that is currently focusing on clinical development of innovative medicines in oncology, immunology, and geriatrics, including therapeutic cancer vaccines. Aston Sci. is constantly listening to the changing needs of the patients and will continue to move forward to improve the lives of patients who suffer from cancer recurrence, metastasis, or side effects during cancer treatment.

Autophagy Science is a drug development company specializing in the development of treatments for intractable diseases.

Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. They are the developer of biomarker-driven anti-cancer targeted therapies and have raised a total funding of $8M over 1 round from 7 investors.

Bionoxx is a research and development company that develops immune regulation-based anticancer drugs to conquer cancer diseases.

Bio-Pharm Solutions is a new drug developer specializing in the central nervous system and rare diseases.

BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. As we are making steady progress in the clinical development, we seek global partners to collaborate in the areas of research and development (R&D) and the commercialization.

BMI KOREA: A DYNAMICALLY-GROWING BIOPHARMACEUTICAL COMPANY, ALWAYS CHALLENGING FOR HEALTHY LIFE OF HUMAN-BEING. BMI is a pharmaceutical and biotechnology company based in South Korea that focuses on development and commercialization of new medicines (incl. biologics) and medical devices. BMI started to operate in 2005, and for more than a decade it has been growing with successful development of new medicines and biologics based on its own novel technologies and know-hows. BMI has specialized in sterile formulation and has developed many products such as HA, PN, PDRN and Botulinum Toxin etc. One of main BMI’s assets is “Hyaluronidase”. BMI has led the market over the last 10 years with two formulations: (A liquid sterile-brand: “Hirax® and a lyophilized sterile power vial- brand: “BM Hylunidase ®”). With these experiences and expertise, BMI has recently developed new generation of it, “Recombinant Hyaluronidase” which is well-known to be used for changing monoclonal antibody’s formulation from IV to SC. On top of that, BMI provides integrated CDMO services to help other pharmaceuticals and biotech companies develop and commercialize medicines. With the most advanced cGMP facilities and R&D center in JEJU and OSONG, BMI can deliver the highly qualified DS, DP and ensure partners’ success to IND, NDA and BLA. Full of speed and customer tailored flexibility are the main strengths.

BMI KOREA: A DYNAMICALLY-GROWING BIOPHARMACEUTICAL COMPANY, ALWAYS CHALLENGING FOR HEALTHY LIFE OF HUMAN-BEING. BMI is a pharmaceutical and biotechnology company based in South Korea that focuses on development and commercialization of new medicines (incl. biologics) and medical devices. BMI started to operate in 2005, and for more than a decade it has been growing with successful development of new medicines and biologics based on its own novel technologies and know-hows. BMI has specialized in sterile formulation and has developed many products such as HA, PN, PDRN and Botulinum Toxin etc. One of main BMI’s assets is “Hyaluronidase”. BMI has led the market over the last 10 years with two formulations: (A liquid sterile-brand: “Hirax® and a lyophilized sterile power vial- brand: “BM Hylunidase ®”). With these experiences and expertise, BMI has recently developed new generation of it, “Recombinant Hyaluronidase” which is well-known to be used for changing monoclonal antibody’s formulation from IV to SC. On top of that, BMI provides integrated CDMO services to help other pharmaceuticals and biotech companies develop and commercialize medicines. With the most advanced cGMP facilities and R&D center in JEJU and OSONG, BMI can deliver the highly qualified DS, DP and ensure partners’ success to IND, NDA and BLA. Full of speed and customer tailored flexibility are the main strengths. For more information, please visit our website below: www.bmikr.co.kr

Boryung is a healthcare investment company founded in 1957 and headquartered in Seoul, South Korea. Following the company’s mission to become an indispensable contributor to human health, we have expanded our business portfolio to the space healthcare industry. Recognizing space as a new growth realm, we acknowledge the increasing number of individuals anticipated to embark on extended space missions, highlighting the importance of ensuring human survival in the hostile space environment. Hence, Boryung believes there will be substantial opportunities to foster new technologies and meet the emerging needs in this field.

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.

Cellatose Therapeutics Co., Ltd. is a company specializing in cell therapy development that was established in August 2017 with the goal of ‘ resolving unmet needs for incurable diseases . ’ The nation's best cell therapy research and development experts are gathering to discover differentiated cell and platform technologies and promote the commercialization of cell therapy products.

Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics. We are committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. We have been at the forefront of biotherapeutic development uncovering new ways of targeting the drivers of disease by creating next-generation biologics and small molecule products. For additional information on our guidelines, please visit: http://tinyurl.com/bdh9bxs9

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

Elixapharmatech is a bio-drug development company that develops immuno-inflammation suppression drugs.

Enzychem Lifesciences, Corp. (KOSDAQ:183490) is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs (Active Pharmaceutical Ingredients). Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments capable of addressing unmet medical needs with R&D-driven approaches under its grand mission of "Saving Human Lives by Overcoming Unmet Medical Needs"​ EC-18, the lead compound of Enzychem Lifesciences, is an immune modulator driven from deer antler that has the potential to be used for a variety of indications. At present, three clinical trials for different indications are being conducted; Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS). In order to facilitate the clinical trial process, Enzychem launched a US operation office in New Jersey on June 28, 2018. Currently, Enzychem Lifesciences is one of the fastest growing life science companies in KOSDAQ Stock Exchange in terms of market capitalization. The company is headquartered in Seoul, Korea.

GC Biopharma (formerly known as Green Cross Corporation, KRX: 006280) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein product manufacturers in the world and has been dedicated to quality healthcare solutions for more than half a century.

Founded in 2016 in South Korea, Genuv(지뉴브) is a clinical-stage biopharma that specializes in discovering and developing innovative therapeutics based on own platform technologies for drug discovery. GENUV is dedicated to the discovery and development of life-transforming therapeutics for patients with debilitating diseases. To do this, we passionately endeavor to advance our own platform technologies and capitalize on our strengths in multi-disciplinary collaborations with external partners. Our current research and development focus is on a) small molecule drugs to treat neurodegenerative diseases through neurogenesis and neural homeostasis and b) antibody drugs for immuno-oncology treatment.

HanAll Biopharma is a global biopharmaceutical company committed to discovering and developing innovative treatments for various diseases. The company has entered into joint research and development agreements with other pharmaceutical companies to explore potential treatments. HanAll Biopharma is dedicated to advancing healthcare through strategic partnerships and cutting-edge research.

HANDOK is a leading innovation-driven pharmaceutical/health-care company in Korea, develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. It was founded in 1954 and has been dedicated to developing and providing innovative pharmaceutical products (Prescription drugs & OTC drugs), medical devices, and in vitro diagnostics. Handok grew with its joint venture partner Hoechst/Aventis/Sanofi from 1964 to 2012. In several areas Handok has also established strategic collaborations with multiple multinational pharmaceutical companies. Handok ended its joint venture relationship with Sanofi in 2012. In 2013, Handok changed its company name from Handok Pharmaceutical Co., Ltd to Handok Inc. and declared its vision to become, “The Health Innovator” as Korea’s leading global healthcare company. “모두의 더 건강한 삶을 위해 대한민국을 대표하는 The Health Innovator가 되겠습니다” 한독은 1954년 창업 이래 세계 유수 제약사들과 협력관계를 맺으며 변화와 성장을 거듭해 왔습니다. 1964년 독일 훽스트와의 합작을 시작으로 합작 파트너가 아벤티스, 사노피로 바뀌는 48년간, 선진 제약기술과 우수의약품을 한국에 도입하며 대한민국 제약산업의 선진화를 이끌었습니다. 1992년 본사 사옥을 강남 테헤란로로 이전하고 충북 음성에 1995년 국내 최고의 GMP 생산시설을 준공한 한독은 일찍이 선진 경영기법과 마케팅 전략을 도입하고 글로벌스탠다드 시스템(Global Standard System)을 갖춰왔습니다. 2012년 10월 독자기업이 되었으며, 2013년 한독약품에서 한독으로 사명을 변경했습니다. 한독은 대한민국을 대표하는 글로벌 토탈헬스케어 기업으로서 The Health Innovator가 되겠다는 비전을 선포하고 바이오 벤처 ‘제넥신’ 지분투자, 세계 1위 제네릭 기업인 이스라엘 테바와 합작회사 ‘한독테바’ 설립, 케토톱으로 유명한 ‘태평양제약 제약사업부문’ 인수, 치료 의료기기 벤처 ‘칼로스메디칼’ 설립, 일본 기능성 원료 회사 ‘테라밸류즈’ 인수 등 미래 성장 동력을 확보하고 글로벌 진출을 확대하기 위한 혁신적인 도전을 이어오고 있습니다. 현재 한독은 전문의약품, 일반의약품, 진단시약과 의료기기, 건강기능식품, 특수의료용도 식품 등 다양한 헬스케어 제품과 서비스를 제공하고 있습니다. 또, 한독은 모두의 더 건강한 삶을 위해 오픈 이노베이션 전략으로 경쟁력을 갖춘 연구개발을 펼쳐 나가고 있으며 혁신 바이오의약품, 표적항암제, 의료기기 개발에 집중하고 있습니다. 2022년 한독은 서울시 강서구 마곡지구에 ‘한독 퓨쳐 콤플렉스’를 준공해 분리되어 있었던 제품개발연구소와 신약개발연구소를 한독 퓨쳐콤플렉스로 통합 이전하며 R&D 역량을 강화했습니다. 더불어 초기 단계의 바이오스타트업을 발굴하고 육성하는 "이노큐브"를 통해 신약개발을 위한 이노베이션플랫폼을 확장했습니다. 한독은 남들보다 한발 앞서, 높은 기준의 윤리경영과 투명경영을 실천하고 있으며, 직원이 행복해야 기업이 함께 성장한다는 믿음으로 직원 스스로 즐겁게 일할 수 있는 기업문화를 만들어 오고 있습니다.

Biologics, Small Molecules

Hanmi Pharmaceutical, Co., Ltd., headquartered in Seoul, South Korea, and established in 1973, has become one of the largest companies not only in Korea but also within the region, selling over 200 products worldwide. Today, Hanmi is also recognized as the No.1 R&D investing company in Korea, spending over 10~15% of the company’s annual revenue in developing next generation Platform Technologies & NCE products.

Hyundai Pharm is eager to share our happiness to all of you. Our all executives and staffs have been building up happiness in Hyundai Pharm as if we are a family. Through this inside circumstance, we are performing moral and qualified management to make all costumers be satisfied with us. Moreover, we have tried to carry out social responsibility with conducting social-minded activities consistently to make the sociality be more peaceful and attractive. We are now going to the next step for the global company. Fear for the changes could be hard to expect for better tomorrow. Hyundai Pharm has been growing up for the best pharmaceutical company in the world through our vision that is “going to the next step with changes and innovation.” For that reason, we are focusing on R&D more to make a new product which contributes to the everyone’s happiness, and eager to be a leading company with our speedy sharing of information and decision. We firmly promise that we will be the best pharmaceutical company in the world in spite of the rapidly changing management circumstances and do our best to achieve our goal.

ILDONG - A global healthcare company dedicated to customer-centric values As a leading pharmaceutical company in South Korea, we have been dedicated and committed to the development and supply of superior pharmaceutical products that contribute to the health and well-being of people around the world. We are steadfast in our vision of continuously growing with our customers as a leading global company by providing solutions for disease prevention and developing new solutions for healthier and happier lives. Ildong has earned the trust of our customers with our ethical drugs franchise for chronic disease and cancer therapies, antibiotics, and digestive and circulatory drugs, in addition to our well-known OTC brands such as Biovita(probiotics product) and Aronamin(multivitamin). We are on the road to reaching our vision of becoming a global total healthcare company with various new drug pipelines including Besivo(hepatitis B therapy), which is the 28th novel drug in South Korea, as well as new innovative drug pipelines and new businesses for health functional foods, medical devices, cosmetics, and beverages.

Clinical-stage Biopharmaceutical Company developing burfiralimab against Chronic hepatitis B and autoimmune diseases. Also Antibodies and small molecules are in the pipeline for oncological and immunological disorders.

ImmunoForge is a biopharmaceutical company that specializes in developing targeted cancer agents for conditions like sarcopenia and rare mutations including BCR-ABL, T315I, RET, and FGFR4.

Innon Energy LTD is a company that empowers Niagara engineers worldwide by supplying Building Automation companies with Niagara 4 products, training, and a 5-star service.

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies.

JD Bioscience (JDB) possesses the core technology and experience to design small molecules for the treatment for a variety of diseases. With its ability and expertise, JBD is developing new drug candidates for metabolic-related diseases.

Jeil Pharmaceutical - Founded in 1959, Jeil has developed and supplied superior pharmaceutical products to promote the happiness and health of mankind and has contributed to the growth and development of the pharmaceutical industry in Korea. Jeil has been listed on KOSPI since 1988. As of 2018, Jeil is constituted of 1143 employees and has sales amount reaching above 680 billion Korean wons. The Central R&D Center established in 1980 forms the core of the R&D activities of Jeil. Currently, as of 2018, the new drug development laboratory, the pharmacology & toxicology laboratory, the organic synthesis laboratory, the formulation laboratory, and the analysis laboratory are actively engaged in conducting research into the complete manufacture and ingredients of innovative new drugs, incrementally modified drugs, and generic drugs. Jeil’s factory established in 1986 and located in Yongin-si, Korea was accredited as fulfilling KGMP in 1987, and produces tablets, capsules, injections, finished pharmaceutical products including patches, and Active Pharmaceutical Ingredients(APIs) such as anti-biotic ingredients, etc. The construction of new factory with the most up-to-dated facilities, which complies with EU-GMP and US-GMP, has been completed in 2016. In May of 2018, Jeil established Pharmaceutical Technology Research Institute, a formulation and analysis lab, at Yongin Technovalley in Yongin-si, Korea to further improve and invest in research and development of Incrementally Modified Drug (IMD) and generic products. Jeil, equipped with global-class research centers and production facilities, has been recognized for its outstanding value on the world market as well. In the ingredients sector, Jeil exports synthetic ingredients such as Cefditoren Pivoxil, Epinastine HCl, etc. to Japan and China, while also supplies finished products such as Kefentech Plaster (Ketoprofen), Cilapenem Injection (Imipenem / Cilastatin Sodium), etc. to more than 40 countries in ASEAN, Central and South America, Africa, etc. Within the South Korean market, Jeil operates a well-trained MR organization to cover the nation-wide market based on science and evidence, and thereby has become a supplier of over 70 prescription drugs and over 30 over-the-counter drugs. Beginning in the period between 1970 and 1980, Jeil has engaged in technological partnerships (licensing) with global pharmaceutical companies to provide the domestic market with outstanding new drugs. It has also been the first Korean company to engage in co-promotion successfully with the globally renowned company Pfizer, executing a win-win strategy with our overseas collaborative partners and thus winning recognition as an advanced pharmaceutical company adapted to internationalized business practices. We thank all of the visitors to our Jeil’s homepage for their interest and encourage you to contact us for further business progress.

JW Pharmaceutical Corp. (formerly Choongwae Pharma) is one of the leading pharmaceutical companies in Korea with core competencies in antibiotics, IV solutions, and anti-cancer treatments. JW is currently exploring targeted therapies in oncology leveraging the collaborative research and development strengths from the JW Drug Discovery Center in Korea and the JW Theriac Corp in the US. This R&D pipeline is driven by our platform technologies that have the potential to eradicate cancer stem cells selectively through a molecularly targeted approach. ------- JW Group consists of JW Holdings, JW Pharmaceutical, JW Medical, JW ShinYak, JW Industrial, JW Life Science, and JW Creagene. JW possesses i) magnificent sales force (900 reps) for the hospital market, ii) strong relationships with managements of hospitals & and hospital pharmacies, iii) excellent rapport with key opinion leaders in endocrinology, gastroenterology, oncology, cardiology, nephrology, urology and the general surgery therapeutic areas. JW's total sales revenue of US $ 0.7 billion was derived from Korea and other several Asian countries in 2012

치료 약물이 없는 뇌퇴행성 질환과 암 질환을 타겟으로 한 혁신 신약 개발 전문기업

Kanaph Therapeutics is developingtherapeutics for oncology by using bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME).

Kolon Pharmaceutical, Inc. was established in 1958 with a mission to contribute on happiness of mankind and social welfare by enhancing people’s quality of life and providing top medical service thru development of innovative drugs with its respect for life and health. Kolon Pharmaceutical is a subsidiary of Kolon group which is one of the biggest industrial conglomerates of Korea that has core business domains in pharmaceuticals, biotechnology, cutting-edge materials, fashion, construction, environment, trade and IT. Kolon group’s health business unit is composed of three subsidiaries and they are Kolon Pharmaceuticals, Kolon Life Science(biotechnology) and Kolon Wellcare(drug store business). Kolon Pharmaceutical developed many outstanding products like Bicogreen for constipation, cold remedy Comy syrup & tablet, anti-fungal drug Konitra and Tamsulo capsule for prostatism with its own technology and also co-developed Brexin tablet(β-Cyclodextrin Prioxicam), Remicut SR capsule(Emedastine difumarate) and Pransus syrup(Pranoprofen) with outstanding pharmaceutical companies like Chiesi, Hisamitsu and Organon since its establishment. Kolon Pharmaceutical is also expanding its global presence by exporting its quality products like Flavon(Ginko biloba ext.), Diverine(Gliclazide), Tavisin(Ofloxacin), Clovana(Diclofenac) and Turant(Acetylcysteine) to Vietnam, Pakistan, Yemen and many other Middle Eastern countries. Our continuous efforts led us to fruitful outcomes in significant areas of our business especially new molecule research, joint research, development of API, new formulation and combination new drug.

LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials.

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to the discovery, development, and commercialization of innovative medicines by leveraging our chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases of highly unmet medical needs. We are advancing sustainable pipelines in therapeutic areas within antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).

LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials such as cathodes, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem is committed to reaching carbon-neutral growth by 2030 and net-zero emissions by 2050 by managing the impacts of climate change and making positive contributions to society through renewable energy and responsible supply chains.

LigaChem Biosciences (formerly LegoChem Biosciences, Inc.) is a clinical stage biopharmaceutical company focused on the development of novel therapeutics utilizing its proprietary drug delivery technologies and therapeutic antibodies. The company's pipeline includes antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer and other serious diseases. LigaChem Biosciences is headquartered in Daejeon, South Korea, with additional offices in Seoul. The company has entered into co-development and license agreements for its ADC programs and has completed acquisitions by other companies. LigaChem Biosciences is committed to advancing innovative treatments for patients in need.

MDimune - The ultimate goal of MDimune Inc. is to provide an innovative platform technology that can revolutionize the paradigm of human therapeutics by achieving target-specific delivery of effective drugs. The precision of this novel technology will enable safer and more effective treatments of many debilitating human diseases and bring hope to patients.

Over the past decades, focusing on a battery of conventional genes/proteins involved in the neurodegeneration has been disappointing in the field of neurodegenerative therapeutics. With the scientific responsibility and integrity, Neuracle Science is a clinical stage biotech company specialized in the development of breakthrough therapies for those who are living with serious and devastating neurodegenerative diseases. We provide a foundation for disease-modifying treatments for neurodegenerative diseases, discovering a completely novel and invaluable gene/protein target with unknown significance using non-biased study. Neuracle Science is based in Seoul, South Korea. We were founded in 2015 by scientific leaders in neuroscience, bioinformatics-based drug discovery, GPCR-mediated signaling, and antibody drug.

Novorex is specialized company in the development of new small molecule drugs targeting mostly oncology and neurology diseases using FBDD and artificial intelligence with pharmaceutical experts. Seamless Drug Discovery is performed using cutting-edge technology that considers the entire process of new drug development. We aim to develop high-efficiency new drugs through drug design that combines biophysical analysis and in vitro/in vivo assay.

인류는 현재 주목할 만한 시대를 살고 있습니다. 우리의 수명은 길어졌으며 앞으로 더욱 더 길어질 것입니다. 여기서 우리는 한가지 질문을 가져봐야 합니다. “진정 늘어난 수명이 행복한 삶이 될 것인가?” 행복한 삶은 오래 사는 것만이 아니라 아름답고 건강하게 살아가는 것입니다. 올리패스는 행복의 새로운 문을 열고자 합니다. 우리는 이러한 기대를 충족시키기 위해 2006년부터 기존 약물의 한계를 극복한 PNA(Peptide Nucleic Acid) 플랫폼을 개발하는데 최선을 다해 오고 있습니다. 올리패스는 차세대 RNA 치료제 개발을 선도하는 생명과학 기업입니다. 모든 질병과 노화를 극복하기 위해서는 각각의 세포들이 건강하고 젊게 유지되어야 합니다. 이 믿음을 갖고 우리는 RNA 치료제 기술을 통해 삶의 질을 획기적으로 높이는 꿈에 다가가고 있습니다. 올리패스에서는 다양한 분야의 과학자들이 각각의 세포들을 치유하고 완전하게 할 수 있는 방법을 찾기 위해 끊임없이 노력하고 있습니다. OliPass PNA 플랫폼 기술을 통해 우리가 이루고자 하는 꿈은 최고의 기술을 저렴하게 널리 쓰일 수 있게 개발해 전 세계 모든 사람들이 의료비 걱정없이 행복하고 건강한 삶을 살 수 있게 하는 것입니다. We are living in remarkable times, in fact when you think about it, over the past 100 years the life expectancy around the globe has almost doubled and we continue, of course, to constantly hope for even greater longevity. But we need to ask ourselves, does this increased longevity lead to a happier life? We all agree that true happiness does not result from just living longer, but also from living well. At OliPass, our mission is to open the door to a new era of healthy and beautiful aging. Since 2006, OliPass has been committed to revolutionizing the life sciences and improving the quality of life. Our research is focused on developing a new generation of therapeutics using our novel PNA based technologies. Thanks to our dedicated team and their hard work, OliPass is now a leading biotech company with OliPass PNA Platform Technology and a growing presence throughout the globe. At OliPass, scientists from diverse fields are constantly working together to find the cures for all diseases. With our innovative OliPass PNA platform technology, our goal is to make the highest quality of science affordable and accessible, so that everyone around the world can enjoy a happy, healthy life. OliPass is dedicated to providing safe and feasible options for healthy aging.

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics based on the science of RNAi to address a wide variety of illnesses. The Company has developed core platforms (asymmetric siRNA, cell-penetrating asiRNA) targeting locally administrable diseases, such as hypertrophic scars, hair loss, and age-related macular degeneration (AMD). OliX's third RNAi therapeutic platform, GalNAc-asiRNA, targets multiple liver diseases, including NASH/diabetes and HBV. For the general welfare of human beings, OliX is constantly endeavoring to become a leader in the global biotechnology industry by innovating and expanding its pipeline, even to the undruggable diseases.

“At Oscotec, our mission is to create values by translating cutting edge science into innovative medicines for clinically unmet needs”

PharmCADD is a company designed to accelerate drug discovery meanwhile performing a design without building or maintaining the infrastructure associated with high-performance computational resources. The platform for both the design and discovery in the PharmCADD is composed of the state-of-the art technology: AI (Artificial intelligence), Molecular Dynamics (MD), Quantum Calculation (QC), and Network theory. AI, which is data-derived technology emerges as a new trend which could potentially be very revolutionary in our modern world. It enables customers to accelerate the search for a certain or specific drug candidate in the vast existence of chemical space. On the other hand, MD and quantum calculation, physics-based technology, enables the customers to characterize potential drug candidates more precisely. The effective combination of the data-derived and physics-based technologies leads to more accurate and speedier drug discovery.

We are a biotech company developing new treatments for patients resistant to existing therapies based on innovative new drug modalities such as antibody-drug conjugate(ADC). Based on our strong R&D capabilities, we have built our next-generation ADC platform PINOT-ADC™ independently and have been working with various partners to research new ADC anticancer treatments. In addition, clinical development and commercialization of NTX-301, a targeted anticancer drug for blood/solid cancer, and NTX-101, a treatment for glaucoma, are underway.

Pin Therapeutics - "Creating Therapeutic Products Degrading Disease-causing Proteins"​

Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM. Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy as well as reduced drug resistance compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).

Prestige Biologics Co., Ltd is a biopharmaceutical CMO, CDMO, CDEMO (Contract Development Engineering Manufacturing Organization) that provides complete solutions to the development and manufacturing requirements in your drug discovery from early stage to product registration and commercialization. Based on our fully established antibody drug & vaccine manufacturing capabilities, we now offer our upgraded CDMO service, CDEMO in which we provide customized engineering solutions for your manufacturing process in a customized manufacturing suite speed-built with our proprietary technology, ALITA Smart BioFactory™.

PROTEINA has developed a first-in-class protein-protein interaction (PPI) analysis platform using proprietary 'single-molecule co-immunoprecipitation' technology. Our platform enables quantitative PPI measurements at the single-molecule level, delivering analyses with unparalleled accuracy and speed. PROTEINA has accumulated extensive know-how in developing assays measuring targeted PPIs as well as the analytic capability to model the efficacy of a drug based on its PPI metrics. Our mission is to revolutionize protein analysis; developing effective, new approaches to diagnosing diseases and discovering new drug candidates using our novel technology. For more information regarding PROTEINA, please visit us at www.proteina.co.kr.

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network. Qurient mainly engages in value creation between early discovery to clinical proof-of-concept. The particular concentration in the value chain creates more efficient organizational structure with clear focus on innovation. Qurient believes late stage development is better handled by fully integrated pharmaceutical/biotech industry with proper marketing function in the therapeutic area. Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders.

ReCerise Therapeutics is a biotechnology company that focuses on developing first-in-class therapeutics and diagnostics targeting liver-specific proteins.

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.

SHINPOONG PHARMACEUTICAL CO.,LTD. is a pharmaceuticals company based out of 733-23 Yoksam-Dong,Kangnam-Gu,Seoul, Seoul, South Korea.

SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials. SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul, South Korea and San Francisco, CA. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVETM platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. Additional information about SillaJen is available at www.sillajen.com.

SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We’re responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at www.skbp.com.

***This page has moved and is no longer active. Please follow us @SK pharmteco for all company news and updates.*** SK biotek Ireland, an SK pharmteco company, is a contract development and manufacturing organization with almost 60 years of active pharmaceutical ingredients manufacturing experience. SK biotek Ireland is the most recent addition to the SK Group. Headquartered in Seoul, Korea, SK Group is ranked in the Top 100* on the Fortune Global 500 list; creating value by taking the initiative in the field of energy and chemicals, information, telecommunications, semiconductors; employing over 109,000 associates globally with annual revenue of US$100 billion. SK biotek Ireland, based in Swords, Co. Dublin, has over 300 associates on campus, comprising of scientists, chemists, engineers, quality professionals carrying out research, development, manufacturing and marketing roles. *2020 Fortune 500 List

SPARK Biopharma - We Provide Small-molecule Therapeutics using Phenotypic Discovery for Improving Human Health.

Surginex is a company that operates a drug discovery platform intended to develop next-generation bio platforms and new drugs. The company specializes in 361 HCT/P allografts and is committed to turning innovative scientific research into practical medical solutions.

TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Our mission is to enhance the hope and happiness of humanity through scientific advancements. TiumBio currently has three leading pipeline assets in clinical trials, with TU2218 being investigated in Phase 2 and TU2670 and TU7710 in Phase 1. TU2218 is an oral immuno-oncology therapy targeting TGF-beta and VEGFR2, while TU2670 is an orally active non-peptide GnRH antagonist. Additionally, TU7710 is a bypass-factor treatment specifically designed for hemophilia patients who have developed neutralizing antibodies. TiumBio is located in Seongnam-si, South Korea and has three subsidiaries including Boston-based biotechnology company, Initium Therapeutics and a CDO compnay, Protium Science.

Wellmarker Bio is a spin-off company from Seoul Asan Medical Center(AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialized in developing predictive biomarkers and first-in-class drugs through profound research know-hows and Research Institute that is comprised of Target discovery department, Drug discovery department, Medicinal chemistry department and CMC department.

YDGLS develops new drugs for various diseases and development & sales of precision medical products & apparatus and healthcare products.

Yuhan Corporation is an integrated healthcare company founded in 1926. It has achieved top market value and sales revenue in Korean pharmaceutical industries, and been awarded for the most respected and trusted company in Korea for recent 11 consecutive years. It has two subsidiaries, Yuhan Chemical and Yuhan Medica, and the affiliates including Joint Ventures with Janssen(Belgium), the Clorox Company(USA), and Kimbery-Clark Corporation(USA). The core business of Yuhan can be classified into Primary & Specialty care, Dietary supplement, Household & Animal care, and contract manufacturing of active pharmaceutical ingredients.

Zymedi is a clinical-stage biopharmaceutical company focused on transforming the role of ARSs (Aminoacyl-tRNA Synthetases) as a novel target for discovering and developing treatments for serious, life-threatening conditions lacking effective therapies or standard care. Our lead asset, ZMA001, is a first-in-class therapeutic that targets Lysyl-tRNA synthetase 1 (KARS1). By controlling monocyte and macrophage infiltration to inhibit inflammation in pulmonary blood vessels, ZMA001 is being developed as a treatment for pulmonary arterial hypertension (PAH). Currently in Phase I trials through a CRADA with the U.S. NIH, ZMA001 shows promise in addressing the root causes of PAH, a market projected to reach $9.7 billion by 2028.